Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms

doi:10.5306/wjco.v17.i1.111426

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

(44)

(41)

(0)

(9)

(466)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jan 24, 2026; 17(1): 111426
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.111426

Table 3 Comparison of relapse-free survival and overall survival between murine double minute 2-negative and murine double minute 2-positive patient groups

Parameter	MDM2-negative (n = 50)	MDM2-positive (n = 21)	P value
Median RFS (months)	68	22	< 0.001
Mean RFS (months)	62.93	21.98
Median OS (months)	Not reached¹	35 (95%CI: 23-47)	0.401
Mean OS (months)	54.8 (95%CI: 42-67.6)	46.2 (95%CI: 33.9-58.5)

¹Median overall survival for the murine double minute 2-negative group was not reached.

RFS: Relapse-free survival; OS: Overall survival; CI: Confidence interval; MDM2: Murine double minute 2.

Full Size Table

Citation: Ebrahim NAA, Elfandy H, Arafat AMA, Darwish AD, Eltohamy MI. Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. World J Clin Oncol 2026; 17(1): 111426
URL: https://www.wjgnet.com/2218-4333/full/v17/i1/111426.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i1.111426

Ebrahim NAA, Elfandy H, Arafat AMA, Darwish AD, Eltohamy MI. Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. World J Clin Oncol 2026; 17(1): 111426 [PMID: 41608334 DOI: 10.5306/wjco.v17.i1.111426]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.